All News
PMR & Popeye's Spinach (10.6.2023)
Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.
Read Article
Rheumatologist SURVEY Question: How often do you start a new PMR patient on 20mg or more of prednisone? Answer here>> https://t.co/beYWFwK1LX
Links:
Dr. John Cush RheumNow ( View Tweet)
Sustained Efficacy of Bimekizumab in PsA
BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, BKZ, in patients with active PsA and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52.
https://t.co/JQ53JV0dvv https://t.co/RQoIXsVnOr
Dr. John Cush RheumNow ( View Tweet)
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/dC9Z7UgkcO https://t.co/44QEittlEX
Dr. John Cush RheumNow ( View Tweet)
2005 study of 364 PMR pts (age 73.4 yrs) - 284 Rx w/ steroids, predictors of relapse =higher initial CS dose & faster CS tapering. Relapse 4-fold higher when the CS tapering rate was fast (HR 4.27). Minimize initial CS dose and taper CS slowly!! https://t.co/hUpBO7fEgh https://t.co/fv9txM0BeH
Dr. John Cush RheumNow ( View Tweet)
Comparison of 354 527 COVID-19 infected vs 6.1 mill controls shows COVID incr risk of alopecia areata (aHR 1.12), alopecia totalis (aHR 1.74), ANCA vasculitis (aHR 2.76), Crohns (aHR), & sarcoidosis (aHR). https://t.co/enwb2taza4 https://t.co/ljY7uMPIrm
Dr. John Cush RheumNow ( View Tweet)
Epidemiology of idiopathic inflammatory myopathies:
- incidence 0.2 - 2 per 100,000 PYs
- prevalence 2 - 25 per 100,000
#s vary w/ age/gender & geography; BUT is still unreported in South America, Africa & Asia https://t.co/fRUNV75xQL
Dr. John Cush RheumNow ( View Tweet)
New download on #PMR available now!
https://t.co/esSuRBwSr0 https://t.co/7d2B2x63tF
Dr. John Cush RheumNow ( View Tweet)
Steroid Tapering in #PMR: What's the Gold Standard?
Dr. Anisha Dua, Chicago, discusses the gold standard tapering of glucocorticoids in polymyalgia rheumatica.
https://t.co/oXVrHuHE58 https://t.co/fHNXodtAeV
Dr. John Cush RheumNow ( View Tweet)
1 in 3 of our pts are on steroids; nice ARD full read review of important papers on steroids 2022-23 written by Prof J Bijlsma, covering:
Mechanisms of action
CV AE
Bone Effects
Infections, COVID-19
Clin trials
Benefit vs Harm
Tapering
GC Guidelines
https://t.co/LnqLk8eKgn https://t.co/5xfvic5YIX
Dr. John Cush RheumNow ( View Tweet)
Pneumothorax in an RA patient is likely from rheumatoid nodules eroding into air spaces in advanced seropositive RA patients. https://t.co/u9rQlKKNKd https://t.co/QKquUngAld https://t.co/e9B3Jx92BW
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/SSKz6RcR5r https://t.co/fLSNHazFS6 https://t.co/pvfrjkOeyW… https://t.co/ASihH17Phu
Links:
Dr. John Cush RheumNow ( View Tweet)
This Tuesday Night Rheumatology focuses on steroid use in #PMR. Join panelists Dr. Max Yates and Dr. Richard Conway. Moderated by Dr. David Liew.
https://t.co/swGbCcoEc9
@drmaxyates1 @richardpaconway @drdavidliew https://t.co/kZQ2wFbjt9
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi Safety and Efficacy in bDMARD-IR Patients with RA: Results Through 5 Years
Now in the RheumNow poster hall: Long-term extension outcomes from SELECT-BEYOND through 5 years in bDMARD-IR patients with RA. Sponsored by AbbVie US Medical Affairs.
https://t.co/xltJjADdHz https://t.co/sytZLayxDZ
Dr. John Cush RheumNow ( View Tweet)
Registration is now open! Early bird pricing is available until 11/30/23. See you there!
https://t.co/zEf9KTXYqX https://t.co/eQTQzgJpVF
Links:
Dr. John Cush RheumNow ( View Tweet)
The frequency of demyelinating Dz (DD) studied in 2260 #SpA pts, finging 18 DD events (IR 31 per 100K PYs) DD at 20 yrs was higher in axSpA than PsA (1.30 vs 0.13%, p= 0.01). DD risk w/ smoking (HR 2.9), axSpA (8.8) & IBD (5.7) -- NOT TNFi! https://t.co/IVoCxd6H0D https://t.co/FQtHuUWYUx
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Steroid Response for a #PMR Diagnosis
Featuring Dr. Jack Cush (Dallas, TX): Exquisite response to prednisone but other red flags!
https://t.co/DCtcZqG5NE https://t.co/Rs9rfds5w0
Dr. John Cush RheumNow ( View Tweet)
TNR: #PMR Diagnosis and Monitoring
Tuesday Night Rheumatology webinar on the diagnosis and monitoring of PMR.
Featuring Panelists, Drs. Claire Owen, Anisha Dua, Stephen Paget and moderated by Jack Cush.
https://t.co/7ewWLAUf4N
@anisha_dua @Rheummd @drceowen https://t.co/GCtYUHBPba
Dr. John Cush RheumNow ( View Tweet)
Multinational study of 47 studies of 11,085 #RA pts showed the prevalence of ANXIETY to range from 2.4% to 77%. Variance due to inconsistent, non-standardized self-report measures and clinical thresholds. Common; but how common? https://t.co/elcxjfSI7N https://t.co/iRNeQy4pEk
Dr. John Cush RheumNow ( View Tweet)
Network metanalysis review of 65 trials (n=5957) looked at Tx effect in Hand #OA. Whereas oral NSAIDs & glucocorticoids’ NMA were effective compared with placebo; intraarticular steroid & hyaluronate, and HCQ and topical NSAIDs were NOT. https://t.co/8CCkfWd80E https://t.co/jpqlq8Xwgp
Dr. John Cush RheumNow ( View Tweet)